Citations

Clear

2 citation(s) found for "Sharma, Jennifer".

High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
(DIAN), the Dominantly Inherited Alzheimer Consortia, Cilia, Roberto , Sharma, Jennifer , Schneider, Lon S. , Graff‐Radford, Neill R. , Mori, Hiroshi , Nübling, Georg, Andaloussi, Samir EL , Svenningsson, Per , Vöglein, Jonathan , Vöglein, Jonathan , Svenningsson, Per , Sturchio, Andrea , (DIAN), the Dominantly Inherited Alzheimer Consortia, Dwivedi, Alok , Malm, Tarja , Wood, Matthew J. A. , Hill, Emily J. , Nübling, Georg , Ezzat, Kariem , Espay, Alberto J.

Mayo Clinic

Journal of Alzheimer's Disease | September 16, 2022 | Volume: 90 | Issue: 1 | Pages: 333-348

10.3233/jad-220808 | PMID 36120786 Get It

Background: In amyloid-positive individuals at risk for Alzheimer’s disease (AD), high soluble 42-amino acid amyloid-β (Aβ42) levels are associated with normal cognition. It is unknown if this relationship applies longitudinally in a genetic cohort. Objective: To test the hypothesis that high Aβ42 preserves normal cognition in amyloid-positive individuals with Alzheimer’s disease (AD)-causing mutations (APP, PSEN1, or PSEN2) to a greater extent than lower levels of brain amyloid, cerebrospinal fluid (CSF) phosphorylated tau (p-tau), or total tau (t-tau). Methods: Cognitive progression was defined as any increase in Clinical Dementia Rating (CDR = 0, normal cognition; 0.5, very mild dementia; 1, mild dementia) over 3 years. Amyloid-positivity was defined as a standard uptake value ratio (SUVR) ≥1.42 by Pittsburgh compound-B positron emission tomography (PiB-PET). We used modified Poisson regression models to estimate relative risk (RR), adjusted for age at onset, sex, education, APOE4 status, and duration of follow-up. The results were confirmed with multiple sensitivity analyses, including Cox regression. Results: Of 232 mutation carriers, 108 were PiB-PET-positive at baseline, with 43 (39.8%) meeting criteria for progression after 3.3±2.0 years. Soluble Aβ42 levels were higher among CDR non-progressors than CDR progressors. Higher Aβ42 predicted a lower risk of progression (adjusted RR, 0.36; 95% confidence interval [CI], 0.19–0.67; p = 0.002) better than lower SUVR (RR, 0.81; 95% CI, 0.68–0.96; p = 0.018). CSF Aβ42 levels predicting lower risk of progression increased with higher SUVR levels. Conclusion: High CSF Aβ42 levels predict normal cognition in amyloid-positive individuals with AD-causing genetic mutations.
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Hart, Steven N. , Sharma, Priyanka , Miron, Penelope , Olswold, Curtis, Slettedahl, Seth W. , Hallberg, Emily, Guidugli, Lucia, Davila, Jaime , Beckmann, Matthias W. , Janni, Wolfgang , Rack, Brigitte , Ekici, Arif B. , Slamon, Dennis J. , Konstantopoulou, Irene , Vratimos, Athanassios, Fountzilas, George , Pelttari, Liisa M. , Tapper, William , Durcan, Lorraine , Cross, Simon S. , Pilarski, Robert , Klemp, Jennifer R. , Cox, Angela , Brauch, Hiltrud , Yannoukakos, Drakoulis , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A. , Eccles, Diana , Wang, Xianshu , Slettedahl, Seth, Davila, Jaime I, Tapper, William J, Shapiro, Charles L. , Klemp, Jennifer, Garber, Judy, Ambrosone, Christine, Couch, Fergus J. , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Fostira, Florentia , Yao, Song , Garber, Judy E. , Ambrosone, Christine B. , Nevanlinna, Heli , Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A , Pelttari, L M , Eccles, Diana , Konstantopoulou, Irene , Slettedahl, Seth W , Hart, Steven N , Cox, Angela , Ekici, Arif B , Davila, Jaime I , Yannoukakos, Drakoulis , Sharma, Priyanka , Brauch, Hiltrud

Mayo Clinic

Journal of Clinical Oncology | December 2, 2014 | Volume: 33 | Issue: 4 | Pages: 304-311

10.1200/jco.2014.57.1414 | PMID 25452441 Get It

Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients. We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations. Results Deleterious mutations were identified in 14.6% of all patients. Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%). Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations. Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer. Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives.